小干扰RNA对脂蛋白的影响:一个系统的审查
Omar Almaadawy1, Mohamed Mar'ey Hesn2, Yomna Ayman Elsalamony3
1Internal Medicine Department, MedStar Health, 201 E. University Pkwy, Baltimore, MD, 21218, USA. omar.a.almaadawy@medstar.net.
概括
小干扰RNA (siRNA) 疗法有效降低脂蛋白[Lp]水平,这是一个关键的心血管风险因素. 这些治疗方法有望带来轻微的副作用,因此需要进一步研究长期结果.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 脂蛋白 (Lp) 是心血管疾病的重要独立风险因素.
- 目前降低Lp (a) 的治疗选择有限.
- 小干扰RNA (siRNA) 代表了一种针对Lp(a) 减少的新型治疗策略.
研究的目的:
- 系统地审查siRNA疗法在降低脂蛋白[Lp]水平方面的疗效.
- 评估最近对siRNA治疗Lp降低的随机对照试验 (RCT) 的结果.
- 评估这些新兴疗法的安全性和耐受性.
主要方法:
- 在主要的科学数据库中进行了全面的文献搜索.
- 包括20个已发表和正在进行的随机对照试验 (RCT).
- 分析了评估siRNA疗法如inclisiran,olpasiran和SLN360对Lp(a),LDL-c和Apolipoprotein B水平的影响的研究.
主要成果:
- siRNA疗法在循环中的Lp(a) 水平上显示出了统计学上显著的降低.
- 观察到低密度脂蛋白胆固醇 (LDL-c) 和无脂蛋白B的同时降低.
- 副作用通常是轻微的,注射部位反应是最常见的副作用.
结论:
- siRNA疗法是一种有前途的新型药物,可以有效降低Lp (a) 水平.
- 这些疗法具有良好的安全性,副作用最小.
- 需要进行进一步的长期研究,以充分确定siRNA在降低心血管风险方面的安全性和有效性.
关键词:
乙类阿波利波蛋白 (B) 是一种阿波利波蛋白.心血管疾病的风险.冠状动脉疾病是一种冠状动脉疾病.超脂血症是因为超脂血症这包括伊朗.这就是LDL-c.降脂疗法是一种降脂疗法.脂蛋白 (a) 是一种蛋白质(一) 一个 (一) 一个 (一) 一个奥尔帕西兰 (Olpasiran) 是一个古老的海峡.随机对照试验是随机对照试验.在SLN360中使用.siRNA 是一个RNA.更多相关视频
11:13Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
Published on: May 9, 2019
8.7K
06:47Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
10.9K
相关概念视频
02:30siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
02:30Small interfering RNAs (siRNA)
3.4K
3.4K
02:15Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
01:23RNA Interference
25.8K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
25.8K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465